Exact Mass: 609.3261282
Exact Mass Matches: 609.3261282
Found 277 metabolites which its exact mass value is equals to given mass value 609.3261282
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Ergocristine
C35H39N5O5 (609.2951043999999)
Ergotaman bearing benzyl, hydroxy, and isopropyl groups at the 5, 12 and 2 positions, respectively, and oxo groups at positions 3, 6, and 18. It is a natural ergot alkaloid. D018373 - Peripheral Nervous System Agents CONFIDENCE Claviceps purpurea sclerotia relative retention time with respect to 9-anthracene Carboxylic Acid is 0.992 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.987 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.984
Tubocurarine
C37H41N2O6+ (609.2964466000001)
Tubocurarine is only found in individuals that have used or taken this drug. It is a neuromuscular blocker and active ingredient in curare; plant based alkaloid of Menispermaceae. [PubChem]Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarines positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH. M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents > M03AA - Curare alkaloids D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists
Dexniguldipine
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000970 - Antineoplastic Agents
tiamulin fumarate
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic
Hydroxydestruxin B
Hydroxydestruxin B is found in herbs and spices. Hydroxydestruxin B is a constituent of the leaves of Sinapis alba (white mustard). Constituent of the leaves of Sinapis alba (white mustard). Hydroxydestruxin B is found in herbs and spices.
Ergocristine
C35H39N5O5 (609.2951043999999)
Niguldipine(+)
2-O-Glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine
tauro-24,25-dihydrofusidate
2,3-deepoxy-2,3-didehydrorhizoxin|2-deoxyrhizoxin|WF-1360F
2alpha,10beta-diacetoxy-9alpha-hydroxy-5alpha-(3-dimethylamino-3-phenylpropanoyl)oxy-3,11-cyclotax-4(20)-en-13-one
Segetalin A
6-(1H-indol-3-ylmethyl)-9-methyl-3,15-di(propan-2-yl)-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosane-2,5,8,11,14,17-hexone
Ergocristinine
C35H39N5O5 (609.2951043999999)
D018373 - Peripheral Nervous System Agents CONFIDENCE Claviceps purpurea sclerotia
Tubocurarine
C37H41N2O6+ (609.2964466000001)
M - Musculo-skeletal system > M03 - Muscle relaxants > M03A - Muscle relaxants, peripherally acting agents > M03AA - Curare alkaloids D018373 - Peripheral Nervous System Agents > D009465 - Neuromuscular Agents > D009466 - Neuromuscular Blocking Agents D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.
Glu Ile Trp Tyr
Glu Ile Tyr Trp
Glu Leu Trp Tyr
Glu Leu Tyr Trp
Glu Trp Ile Tyr
Glu Trp Leu Tyr
Glu Trp Tyr Ile
Glu Trp Tyr Leu
Glu Tyr Ile Trp
Glu Tyr Leu Trp
Glu Tyr Trp Ile
Glu Tyr Trp Leu
His Lys Tyr Tyr
His Tyr Lys Tyr
His Tyr Tyr Lys
Ile Glu Trp Tyr
Ile Glu Tyr Trp
Ile Trp Glu Tyr
Ile Trp Tyr Glu
Ile Tyr Glu Trp
Ile Tyr Trp Glu
Lys His Tyr Tyr
Lys Asn Trp Tyr
Lys Asn Tyr Trp
Lys Trp Asn Tyr
Lys Trp Tyr Asn
Lys Tyr His Tyr
Lys Tyr Asn Trp
Lys Tyr Trp Asn
Lys Tyr Tyr His
Leu Glu Trp Tyr
Leu Glu Tyr Trp
Leu Trp Glu Tyr
Leu Trp Tyr Glu
Leu Tyr Glu Trp
Leu Tyr Trp Glu
Asn Lys Trp Tyr
Asn Lys Tyr Trp
Asn Trp Lys Tyr
Asn Trp Tyr Lys
Asn Tyr Lys Trp
Asn Tyr Trp Lys
Trp Glu Ile Tyr
Trp Glu Leu Tyr
Trp Glu Tyr Ile
Trp Glu Tyr Leu
Trp Ile Glu Tyr
Trp Ile Tyr Glu
Trp Lys Asn Tyr
Trp Lys Tyr Asn
Trp Leu Glu Tyr
Trp Leu Tyr Glu
Trp Asn Lys Tyr
Trp Asn Tyr Lys
Trp Tyr Glu Ile
Trp Tyr Glu Leu
Trp Tyr Ile Glu
Trp Tyr Lys Asn
Trp Tyr Leu Glu
Trp Tyr Asn Lys
Tyr Glu Ile Trp
Tyr Glu Leu Trp
Tyr Glu Trp Ile
Tyr Glu Trp Leu
Tyr His Lys Tyr
Tyr His Tyr Lys
Tyr Ile Glu Trp
Tyr Ile Trp Glu
Tyr Lys His Tyr
Tyr Lys Asn Trp
Tyr Lys Trp Asn
Tyr Lys Tyr His
Tyr Leu Glu Trp
Tyr Leu Trp Glu
Tyr Asn Lys Trp
Tyr Asn Trp Lys
Tyr Trp Glu Ile
Tyr Trp Glu Leu
Tyr Trp Ile Glu
Tyr Trp Lys Asn
Tyr Trp Leu Glu
Tyr Trp Asn Lys
Tyr Tyr His Lys
Tyr Tyr Lys His
b-D-Glucopyranosiduronic acid, (3a,5b)-24-[(carboxymethyl)amino]-24-oxocholan-3-yl
Hydroxydestruxin B
S(+)-Niguldipine hydrochloride
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000970 - Antineoplastic Agents C93038 - Cation Channel Blocker
Dexniguldipine
D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators D000970 - Antineoplastic Agents C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C1744 - Multidrug Resistance Modulator C93038 - Cation Channel Blocker
L-Valinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-methylalanyl-N-[(1S,2S)-1-[(1R)-2-carboxy-1-methoxyethyl]-2-methylbutyl]-N-methyl-
2-O-Glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine
1-O-palmitoyl-2-O-glutaroyl-sn-glycero-3-phosphocholine
(2E,4E,7E,9S)-10-[(4S,4aR,6R,8S,8aR)-4-[[(2S)-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-6-yl]-9-hydroxydeca-2,4,7-trienoic acid
(2E,4E)-10-[(4S,4aR,6R,8S,8aR)-4-[[(2S)-2-hydroxy-2-[(2R,5R,6R)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]acetyl]amino]-8-methoxy-7,7-dimethyl-4a,6,8,8a-tetrahydro-4H-pyrano[3,2-d][1,3]dioxin-6-yl]-9-oxodeca-2,4-dienoic acid
[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] (9Z,12Z)-octadeca-9,12-dienoate
2-[[(2E)-2-(16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene)-6-methylheptanoyl]amino]ethanesulfonic acid
D010592 - Pharmaceutic Aids
Tubocurarine chloride pentahydrate (+)
C37H41N2O6+ (609.2964466000001)
5-O-(4,4-diphenylpiperidin-1-yl) 3-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)-1-propyl-4H-pyridine-3,5-dicarboxylate
methyl 4-O-(5-aminopentyl)-alpha-D-rhamnopyranosyl-(1->2)-4-deoxy-4-formamido-alpha-D-rhamnopyranosyl-(1->3)-4-deoxy-4-formamido-alpha-D-rhamnopyranoside
C26H47N3O13 (609.3108732000001)
[3-acetyloxy-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(3-octanoyloxy-2-pentadecanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(3-nonanoyloxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(2-octadecanoyloxy-3-pentanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(2-icosanoyloxy-3-propanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(2-heptadecanoyloxy-3-hexanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(3-heptanoyloxy-2-hexadecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(3-butanoyloxy-2-nonadecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(3-decanoyloxy-2-tridecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[(2-dodecanoyloxy-3-undecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
(1S)-10,25-dimethoxy-15,15,30-trimethyl-7,23-dioxa-30-aza-15-azoniaheptacyclo[22.6.2.23,6.18,12.118,22.027,31.016,34]hexatriaconta-3(36),4,6(35),8(34),9,11,18(33),19,21,24,26,31-dodecaene-9,21-diol
C37H41N2O6+ (609.2964466000001)
(6aS,9S)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
C35H39N5O5 (609.2951043999999)
(2S)-2-amino-3-[[(2R)-3-decanoyloxy-2-tridecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
3-[(3-Acetyloxy-2-henicosanoyloxypropoxy)-hydroxyphosphoryl]oxy-2-aminopropanoic acid
(E)-N-[2-[2-[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-3,4-dihydroxy-3,4-dihydro-2H-pyran-5-yl]-9,11-dimethyltridec-2-enamide
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydec-4-en-2-yl]hexanamide
C28H51NO13 (609.3360236000001)
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodec-4-en-2-yl]butanamide
C28H51NO13 (609.3360236000001)
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyoct-4-en-2-yl]octanamide
C28H51NO13 (609.3360236000001)
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxynon-4-en-2-yl]heptanamide
C28H51NO13 (609.3360236000001)
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytridec-4-en-2-yl]propanamide
C28H51NO13 (609.3360236000001)
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradec-4-en-2-yl]acetamide
C28H51NO13 (609.3360236000001)
N-[(E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxyundec-4-en-2-yl]pentanamide
C28H51NO13 (609.3360236000001)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-undec-4-enoyl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate
(2S)-2-amino-3-[[(2R)-2-decanoyloxy-3-tridecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-3-dodecanoyloxy-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
(2S)-2-amino-3-[[(2R)-2-dodecanoyloxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-O-Glutaroyl-1-O-palmitoyl-sn-glycero-3-phosphocholine
A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and glutaroyl groups at positions 1 and 2 respectively.
PAF(22:6)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
NXT629
C35H39N5O3S (609.2773463999999)
NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively[1]. NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models[2].
n-({6-[3-(6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-2-hydroxybutyl]-4-hydroxy-5,5-dimethyloxan-2-yl}(methoxy)methyl)-2-hydroxy-3-(hydroxymethyl)-5-methylhex-5-enimidic acid
(2s,3s)-n-[(s)-[(4r,6r)-6-[(2s,3r)-3-[(3s)-6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-2-hydroxybutyl]-4-hydroxy-5,5-dimethyloxan-2-yl](methoxy)methyl]-2-hydroxy-3-methoxy-5-methylhex-5-enimidic acid
1,10-dihydroxy-16-(3-hydroxy-2-methylpropyl)-6-isopropyl-5,8,9-trimethyl-3-(sec-butyl)-3h,6h,9h,12h,13h,16h,19h,20h,21h,21ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclononadecane-4,7,14,17-tetrone
2-({6-[9a,11a-dimethyl-7-(sulfooxy)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxy-2-methylheptylidene}amino)-3-methylpentanoic acid
2,10-bis(acetyloxy)-3-hydroxy-4,14,15,15-tetramethyl-8-methylidene-13-oxotetracyclo[9.3.1.0¹,⁹.0⁴,⁹]pentadecan-7-yl 3-(dimethylamino)-3-phenylpropanoate
8-hydroxy-10-[3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-2,7-dimethyl-6,11,19-trioxatricyclo[14.3.1.0⁵,⁷]icosa-3,13-diene-12,18-dione
(1s,11r,18s,20r,21r,22s)-10-{3-ethyl-8-methoxy-6h,7h-indolo[2,3-a]quinolizin-2-yl}-17-methyl-12-oxa-8,17-diazaheptacyclo[15.5.2.0¹,¹⁸.0²,⁷.0⁸,²².0¹¹,²¹.0¹⁵,²⁰]tetracosa-2,4,6,9,14-pentaen-17-ium
[C40H41N4O2]+ (609.3229345999999)
(3s,6s,9s,15ar)-1,4,7-trihydroxy-9-isopropyl-6-[(1-methoxyindol-3-yl)methyl]-3-(6-oxooctyl)-3h,6h,9h,12h,13h,14h,15h,15ah-pyrido[1,2-a]1,4,7,10-tetraazacyclododecan-10-one
(3s,6s,9s,16s,21as)-3-[(2s)-butan-2-yl]-1,10-dihydroxy-16-[(2s)-3-hydroxy-2-methylpropyl]-6-isopropyl-5,8,9-trimethyl-3h,6h,9h,12h,13h,16h,19h,20h,21h,21ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclononadecane-4,7,14,17-tetrone
(2r,3s)-n-[(s)-[(2r,4s,6s)-6-[(2s,3s)-3-[(3r)-6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-2-hydroxybutyl]-4-hydroxy-5,5-dimethyloxan-2-yl](methoxy)methyl]-2-hydroxy-3-(hydroxymethyl)-5-methylhex-5-enimidic acid
(4s,7r)-n-[(1s,2s,4r,7s)-7-benzyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
C35H39N5O5 (609.2951043999999)
(4s,7r,8s,9s,13z,16s)-4-{[(2s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-8-hydroxy-5,5,7,9-tetramethyl-16-[(1e)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
C31H47NO9S (609.2971372000001)
(2s,3s)-2-{[(2r,6r)-6-[(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-7-(sulfooxy)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxy-2-methylheptylidene]amino}-3-methylpentanoic acid
(3s,6s,9s,16r,21as)-3-[(2s)-butan-2-yl]-1,10-dihydroxy-16-(3-hydroxy-2-methylpropyl)-6-isopropyl-5,8,9-trimethyl-3h,6h,9h,12h,13h,16h,19h,20h,21h,21ah-pyrrolo[1,2-d]1-oxa-4,7,10,13,16-pentaazacyclononadecane-4,7,14,17-tetrone
(2s,3s)-2-{[(6r)-6-[(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-7-(sulfooxy)-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxy-2-methylheptylidene]amino}-3-methylpentanoic acid
(2e,4e,7e,9s)-10-[(4s,4ar,6r,8s,8ar)-4-{[(2r)-1,2-dihydroxy-2-[(2r,5r,6r)-2-methoxy-5,6-dimethyl-4-methylideneoxan-2-yl]ethylidene]amino}-8-methoxy-7,7-dimethyl-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]-9-hydroxydeca-2,4,7-trienoic acid
n-({6-[3-(6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydro-2-benzopyran-3-yl)-2-hydroxybutyl]-4-hydroxy-5,5-dimethyloxan-2-yl}(methoxy)methyl)-2-hydroxy-3-methoxy-5-methylhex-5-enimidic acid
(4r,7r)-n-[(1s,4r,7s)-7-benzyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
C35H39N5O5 (609.2951043999999)
(1r,2r,5r,7r,8s,10s,13e,16r)-8-hydroxy-10-[(2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-2,7-dimethyl-6,11,19-trioxatricyclo[14.3.1.0⁵,⁷]icosa-3,13-diene-12,18-dione
(1r,2r,3e,5r,7r,8s,10s,13e,16r)-8-hydroxy-10-[(2s,3r,4e,6e,8e)-3-methoxy-4,8-dimethyl-9-(2-methyl-1,3-oxazol-4-yl)nona-4,6,8-trien-2-yl]-2,7-dimethyl-6,11,19-trioxatricyclo[14.3.1.0⁵,⁷]icosa-3,13-diene-12,18-dione
1,4,7,10,13-pentahydroxy-6-(1h-indol-3-ylmethyl)-3,15-diisopropyl-9-methyl-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one
(1s,11r,17s,18s,20r,21r,22s)-10-{3-ethyl-8-methoxy-6h,7h-indolo[2,3-a]quinolizin-2-yl}-17-methyl-12-oxa-8,17-diazaheptacyclo[15.5.2.0¹,¹⁸.0²,⁷.0⁸,²².0¹¹,²¹.0¹⁵,²⁰]tetracosa-2,4,6,9,14-pentaen-17-ium
[C40H41N4O2]+ (609.3229345999999)
4-{[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-8-hydroxy-5,5,7,9-tetramethyl-16-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
C31H47NO9S (609.2971372000001)
(3s,6s,9s,14ar)-1,4,7-trihydroxy-6-[(1-methoxyindol-3-yl)methyl]-3-(6-oxooctyl)-9-(sec-butyl)-3h,6h,9h,12h,13h,14h,14ah-pyrrolo[1,2-a]1,4,7,10-tetraazacyclododecan-10-one
(2s,3s)-n-[(s)-[(2s,4r,6r)-6-[(2s,3r)-3-[(3r)-6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-2-hydroxybutyl]-4-hydroxy-5,5-dimethyloxan-2-yl](methoxy)methyl]-2-hydroxy-3-methoxy-5-methylhex-5-enimidic acid
(4r,7r)-n-[(1s,2s,4r,7s)-7-benzyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
C35H39N5O5 (609.2951043999999)
n-{7-benzyl-2-hydroxy-4-isopropyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl}-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
C35H39N5O5 (609.2951043999999)